ANI Pharmaceuticals (ANIP) legal chief reports stock sale and tax withholdings

Rhea-AI Filing Summary

ANI Pharmaceuticals senior executive Meredith W. Cook reported several stock transactions involving company common shares. On February 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock in an open-market sale at an average price of $76.8 per share under a Rule 10b5-1 trading plan adopted on September 15, 2025.

On February 12 and February 14, 2026, a total of 3,313 shares were withheld to cover tax obligations in connection with the vesting of previously granted restricted stock awards, at prices of $76.7 and $77.36 per share, respectively. After these transactions, she directly owned 67,550 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 500 shares ($38,400)

Net Sell 3 txns

Insider Cook Meredith

Role SR. VP, GENERAL COUNSEL & SEC.

Sold 500 shs ($38K)

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	1,779	$77.36	$138K
Sale	Common Stock	500	$76.80	$38K
Tax Withholding	Common Stock	1,534	$76.70	$118K

Holdings After Transaction: Common Stock — 67,550 shares (Direct)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,243 shares of restricted stock, the grant of which was previously reported on February 18, 2025. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cook Meredith

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP, GENERAL COUNSEL & SEC.

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		1,534	D	$76.7	69,829	D
Common Stock	02/13/2026		S(2)		500	D	$76.8	69,329	D
Common Stock	02/14/2026		F(3)		1,779	D	$77.36	67,550	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,243 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.

3. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 3,691 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ANI Pharmaceuticals (ANIP) report for Meredith Cook?

ANI Pharmaceuticals reported that executive Meredith W. Cook sold 500 common shares and had 3,313 shares withheld for taxes. The tax withholdings related to vesting restricted stock, while the 500-share sale was an open-market transaction under a pre-established Rule 10b5-1 plan.

How many ANI Pharmaceuticals (ANIP) shares does Meredith Cook own after these transactions?

After the reported transactions, Meredith W. Cook directly owns 67,550 ANI Pharmaceuticals common shares. This figure reflects the impact of both the 500-share open-market sale and the 3,313 shares withheld to satisfy tax obligations tied to restricted stock vesting events.

Were any of Meredith Cook’s ANI Pharmaceuticals (ANIP) transactions tax withholdings?

Yes. On February 12 and February 14, 2026, a combined 3,313 shares were withheld for tax purposes. These withholdings were exempt under Rule 16(b)-3 and related to the vesting of restricted stock awards previously granted and disclosed in earlier ANI Pharmaceuticals filings.

Was the ANI Pharmaceuticals (ANIP) insider sale by Meredith Cook made under a Rule 10b5-1 plan?

Yes. The 500-share sale on February 13, 2026 was executed under a Rule 10b5-1 trading plan. The filing states this plan was adopted by Meredith W. Cook on September 15, 2025, providing a pre-arranged framework for selling shares over time.

At what prices were Meredith Cook’s ANI Pharmaceuticals (ANIP) transactions executed?

The tax-withholding dispositions occurred at $76.7 and $77.36 per share, while the open-market sale was executed at $76.8 per share. These prices apply to common stock transactions reported around the mid-February 2026 vesting and trading activity.

What is Meredith Cook’s role at ANI Pharmaceuticals (ANIP) in this insider filing?

In this insider report, Meredith W. Cook is identified as an officer of ANI Pharmaceuticals, serving as Senior Vice President, General Counsel and Secretary. The filing confirms she is not listed as a director or 10% owner but reports transactions in her capacity as an officer.